Subscribe

Articles

Repotrectinib, an Investigational TKI, Induces Response in ROS1-Fusion–Positive NSCLC
Repotrectinib, an Investigational TKI, Induces Response in ROS1-Fusion–Positive NSCLC
By Wayne Kuznar
Lung Cancer
TON - October 2019, Vol 12, No 5
Chicago, IL—Expanded data from an early phase 1/2 clinical trial showed that treatment with repotrectinib, an investigational tyrosine kinase inhibitor (TKI) with potent selectivity against tumors with ROS1 rearrangement, induced a response in 9 of 11 patients with TKI-naïve, ROS1-fusion–positive non–small-cell lung cancer (NSCLC). Read More ›
Single-Agent ONC201 Induces Responses in Patients with Hard-to-Treat Recurrent High-Grade Gliomas
Single-Agent ONC201 Induces Responses in Patients with Hard-to-Treat Recurrent High-Grade Gliomas
By Wayne Kuznar
Emerging Therapies
TON - October 2019, Vol 12, No 5
Chicago, IL—High-grade gliomas harboring the histone 3 (H3) K27M mutation are lethal brain tumors associated with a poor prognosis. At the 2019 American Society of Clinical Oncology Annual Meeting, results from a clinical trial showed that treatment with ONC201, a unique, small molecule DRD2 antagonist, resulted in durable tumor regression in adults with recurrent high-grade H3 K27M-mutant gliomas. Read More ›
Reduced-Intensity Chemotherapy for Frail Elderly Patients with Advanced Gastroesophageal Cancer
By Phoebe Starr
Geriatric Cancer
TON - October 2019, Vol 12, No 5
Chicago, IL—Reduced-dose chemotherapy is as effective as full-dose chemotherapy in frail elderly patients with advanced gastroesophageal cancer, according to results of the phase 3 GO2 clinical trial presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. Lower doses of oxaliplatin plus capecitabine (OCap) led to similar survival but improved quality of life compared with higher doses of that regimen in this patient population. Read More ›
FDA Approves Inrebic for the Treatment of Patients with Myelofibrosis
FDA Updates
TON - October 2019, Vol 12, No 5
On August 16, 2019, the FDA approved fedratinib (Inrebic; Celgene) for the treatment of patients with intermediate-2 or high-risk primary or secondary (post–polycythemia vera or post–essential thrombocythemia) myelofibrosis. Read More ›
Fixed-Duration Venetoclax plus Obinutuzumab New Standard of Care for Front-Line Treatment of Patients with CLL and Comorbidities
Fixed-Duration Venetoclax plus Obinutuzumab New Standard of Care for Front-Line Treatment of Patients with CLL and Comorbidities
By Phoebe Starr
Leukemia
TON - October 2019, Vol 12, No 5
In the phase 3 CLL14 clinical trial, fixed-duration venetoclax plus obinutuzumab was superior to chlor­ambucil plus obinutuzumab as front-line therapy in older patients with chronic lymphocytic leukemia (CLL) and comorbidities. The fixed-duration regimen significantly improved progression-free survival (PFS), complete response (CR) rate, and minimal residual disease (MRD) negativity versus chlorambucil plus obinutuzumab, and was superior in patients with poor prognostic factors, such as unmutated IGHV and TP53 alterations. Read More ›
Darzalex Combination Receives Approval for First-Line Treatment of Patients with Multiple Myeloma Eligible for Transplant
FDA Updates, Multiple Myeloma, In the News
Web Exclusives
On September 26, 2019, the FDA approved daratumumab (Darzalex; Janssen) in combination with bortezomib, thalidomide, and dexamethasone for the treatment of newly diagnosed patients with multiple myeloma who are eligible for autologous stem-cell transplant (ASCT). The FDA granted this application priority review. Read More ›
From the Editor - TON August 2019
From the Editor - TON August 2019
By Beth Faiman, PhD, APRN-BC, AOCN
From the Editor
TON - August 2019, Vol 12, No 4
The August issue of The Oncology Nurse-APN/PA (TON) is filled with important news and insights for today’s oncology nurse. We begin our coverage with a profile of the Fox Chase Cancer Center, Philadelphia, PA, as we speak with Elizabeth Capaldi, RN, BSN, OCN, who discusses her role as a nurse in the center’s infusion room, the significant life events that influenced her choice to become an oncology nurse, the rewards of her job, and what she finds exciting in the evolving field of oncology. Read More ›
Fox Chase Cancer Center: Making a Difference in Patients' Lives
Cancer Center Profile
TON - August 2019, Vol 12, No 4
Fox Chase Cancer Center (Fox Chase) is a National Cancer Institute–designated Comprehensive Cancer Center research facility and hospital located in Philadelphia, PA. It is part of the Temple University Health System and has a staff of 2400 plus more than 250 volunteers. The world-class center employs top cancer specialists who are dedicated to diagnosing, treating, and managing all types of cancer. Fox Chase is consistently highly rated among cancer centers in the United States. Read More ›
Preserving Sexual Function in Women After Cancer Treatment
Preserving Sexual Function in Women After Cancer Treatment
By Meg Barbor, MPH
ONS
TON - August 2019, Vol 12, No 4
Anaheim, CA—The primary reason that nurses cite for not approaching the topic of sexual health with their patients is lack of knowledge. At the Oncology Nursing Society (ONS) 44th Annual Congress, Lisa Chism, DNP, APRN, NCMP, FAANP, Clinical Director, Women’s Wellness Clinic, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, set out to change that by arming oncology nurses with enough knowledge to broach the subject confidently with their female patients. Read More ›
MONALEESA-7 Sets New Standard of Care for Premenopausal Women with Advanced Breast Cancer
By Phoebe Starr
Breast Cancer
TON - August 2019, Vol 12, No 4
Chicago, IL—The addition of the ­cyclin-dependent kinase (CDK)4/CDK6 inhibitor ribociclib to standard endocrine therapy significantly extended overall survival (OS) compared with endocrine therapy alone in premenopausal women with hormone receptor (HR)-positive, HER2-negative advanced breast cancer, according to results of the phase 3 MONALEESA-7 clinical trial, presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. Read More ›

Page 145 of 376


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, TON print publication, and TON Bi-Weekly e‑newsletter.

Subscribe

Amplity

© Amplity, Inc. All Rights Reserved. Privacy Policy.